Outsourced Pharma Capacity Update Videos - Cell & Gene

1. The Future Of Lentiviral Vector Innovation And Access 10/17/2025

   Founded on lentiviral vector design and manufacturing excellence, VBM and the LENTIVERSE™ technology platform provide a full suite of tools to quickly deliver state-of-the-art therapies and develop next-generation products.

2. Minaris Advanced Therapies Capacity Update October 2025: Cell & Gene Therapy 10/17/2025

   During this session, we will provide an overview of our capabilities, including our contract testing services, and an update on our current capacity.

3. Ascend & ABL Inc. Capacity Update October 2025: Cell & Gene Therapy 10/17/2025

   Operating from state-of-the-art GMP facilities, we provide end-to-end services to commercial, academic, and government clients, spanning process innovation through development, GMP manufacturing, QC testing, to aseptic fill/finish.

4. Andelyn Biosciences Capacity Update October 2025: Cell & Gene Therapy 10/17/2025

   A risk-based framework for identity testing of ancillary raw materials in gene therapy is presented, with emphasis on implementation based on product contact, material classification, and manufacturing stage.

5. Viralgen Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

   As a leading CDMO in AAV manufacturing, Viralgen facilitates rapid transition to cGMP with a proven platform and an impeccable 100% IND success rate. Discover how Viralgen drives industry progress.

6. Minaris Advanced Therapies Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

   With a robust track record of more than 7,500 GMP batches and proven platforms for multiple modalities, Minaris delivers speed, scalability, and reliability to help therapeutic developers bring cures to patients faster.

7. Excellos Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

   Excellos leverages its extensive starting material expertise as a key differentiator. Explore how our deep understanding of partner-sourced raw materials, quality control, and supply chain management creates significant value for our clients.

8. A Concept-To-Commercial Gene Therapy CDMO 7/28/2025

   The Curator™ adherent platform has been used to manufacture more than 450 Phase 1 and 2 clinical batches, spanning over 17 years and covering a variety of serotypes and indications.

9. FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

   Director of Commercial Development, Serat Ali, describes FDBs' Advanced Therapy capabilities, discusses their global facilities network, and provides a capacity update.

10. Vinta Bio Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Uncover how an intensified adherent AAV manufacturing process is unlocking high-yield, low-impurity clinical production with over 95% full capsids in a streamlined, compact platform.